New perspectives on inhaled drug delivery and systemic bioactivity.
作者信息
Lipworth B J
出版信息
Thorax. 1995 Feb;50(2):105-10. doi: 10.1136/thx.50.2.105.
Abstract
摘要
相似文献
1
New perspectives on inhaled drug delivery and systemic bioactivity.吸入给药与全身生物活性的新视角。
Thorax. 1995 Feb;50(2):105-10. doi: 10.1136/thx.50.2.105.
2
Pharmacokinetic optimisation of asthma treatment.哮喘治疗的药代动力学优化
Clin Pharmacokinet. 1994 May;26(5):396-418. doi: 10.2165/00003088-199426050-00006.
3
Long-acting beta-agonists and inhaled corticosteroids: is the whole greater than the sum of its parts?长效β受体激动剂与吸入性糖皮质激素：整体是否大于部分之和？
J Allergy Clin Immunol. 2010 Feb;125(2):357-8. doi: 10.1016/j.jaci.2009.12.021.
4
When should a long acting {beta} agonist be added to an inhaled corticosteroid?长效β受体激动剂应在何时添加到吸入性糖皮质激素中？
Thorax. 2005 Sep;60(9):710. doi: 10.1136/thx.2005.042028.
5
Pharmacological management--inhaled treatment.药理管理——吸入治疗。
BMJ. 2006 Jun 17;332(7555):1439-41. doi: 10.1136/bmj.332.7555.1439.
6
[Chronotherapy of asthma].
Internist (Berl). 1991 Jul;32(7):411-7.
7
Description of a randomised controlled trial of inhaled corticosteroid/fast-onset LABA reliever therapy in mild asthma.轻度哮喘吸入性糖皮质激素/速效长效β2受体激动剂缓解治疗的随机对照试验描述
Eur Respir J. 2016 Mar;47(3):981-4. doi: 10.1183/13993003.01692-2015. Epub 2016 Feb 4.
8
Long-acting beta-agonists with and without inhaled corticosteroids and catastrophic asthma events.长效β-激动剂联合或不联合吸入性皮质类固醇与灾难性哮喘事件。
Am J Med. 2010 Apr;123(4):322-8.e2. doi: 10.1016/j.amjmed.2009.07.035. Epub 2010 Feb 20.
9
An update on the safety of long-acting beta-agonists in asthma patients using inhaled corticosteroids.吸入皮质类固醇治疗哮喘患者中长效β-激动剂的安全性更新。
Expert Opin Drug Saf. 2010 May;9(3):407-19. doi: 10.1517/14740330903535852.
引用本文的文献
1
5-Azacytidine inhaled dry powder formulation profoundly improves pharmacokinetics and efficacy for lung cancer therapy through genome reprogramming.5-氮杂胞苷吸入干粉制剂通过基因组重编程显著改善肺癌治疗的药代动力学和疗效。
Br J Cancer. 2020 Apr;122(8):1194-1204. doi: 10.1038/s41416-020-0765-2. Epub 2020 Feb 27.
2
Biological Obstacles for Identifying - Correlations of Orally Inhaled Formulations.识别经口吸入制剂相关性的生物学障碍
Pharmaceutics. 2019 Jul 5;11(7):316. doi: 10.3390/pharmaceutics11070316.
3
Clinical pharmacokinetics of inhaled antimicrobials.吸入性抗菌药物的临床药代动力学
Clin Pharmacokinet. 2015 May;54(5):473-92. doi: 10.1007/s40262-015-0250-x.
4
Influence of PEI as a core modifying agent on PLGA microspheres of PGE₁, a pulmonary selective vasodilator.聚醚酰亚胺（PEI）作为核心修饰剂对肺选择性血管舒张剂 PGE₁的 PLGA 微球的影响。
Int J Pharm. 2011 Jul 15;413(1-2):51-62. doi: 10.1016/j.ijpharm.2011.04.017. Epub 2011 Apr 16.
5
The inhaled glucocorticoid fluticasone propionate efficiently inactivates cytochrome P450 3A5, a predominant lung P450 enzyme.吸入性糖皮质激素丙酸氟替卡松能有效地使细胞色素 P4503A5 失活，细胞色素 P4503A5 是肺内主要的 P450 酶。
Chem Res Toxicol. 2010 Aug 16;23(8):1356-64. doi: 10.1021/tx100124k.
6
New treatment options in allergic rhinitis: patient considerations and the role of ciclesonide.变应性鼻炎的新治疗选择：患者考虑因素和环索奈德的作用。
Ther Clin Risk Manag. 2008 Apr;4(2):353-61. doi: 10.2147/tcrm.s1266.
7
In vitro and in vivo aspects of cascade impactor tests and inhaler performance: a review.级联撞击器测试与吸入器性能的体外和体内研究进展：综述
AAPS PharmSciTech. 2007 Dec 21;8(4):E110. doi: 10.1208/pt0804110.
8
Safety of the newer inhaled corticosteroids in childhood asthma.新型吸入性糖皮质激素在儿童哮喘中的安全性。
Paediatr Drugs. 2003;5(7):481-504. doi: 10.2165/00128072-200305070-00005.
9
Deposition and effects of inhaled corticosteroids.吸入性糖皮质激素的沉积与作用
Clin Pharmacokinet. 2003;42(6):529-44. doi: 10.2165/00003088-200342060-00003.
10
Clinical pharmacokinetics of inhaled budesonide.吸入用布地奈德的临床药代动力学
Clin Pharmacokinet. 2001;40(6):427-40. doi: 10.2165/00003088-200140060-00004.
本文引用的文献
1
Comparison of the extrapulmonary beta2-adrenoceptor responses and pharmacokinetics of salbutamol given by standard metered dose-inhaler and modified actuator device.标准定量吸入器与改良雾化器装置给予沙丁胺醇后肺外β2-肾上腺素能受体反应及药代动力学的比较。
Br J Clin Pharmacol. 1993 Nov;36(5):445-50. doi: 10.1111/j.1365-2125.1993.tb00393.x.
2
The influence of orally deposited budesonide on the systemic availability of budesonide after inhalation from a Turbuhaler.口服布地奈德对使用都保吸入布地奈德后其全身可用性的影响。
Br J Clin Pharmacol. 1993 Sep;36(3):211-4. doi: 10.1111/j.1365-2125.1993.tb04219.x.
3
Large volume spacer devices and the influence of high dose beclomethasone dipropionate on hypothalamo-pituitary-adrenal axis function.大容量储雾罐装置及高剂量二丙酸倍氯米松对下丘脑-垂体-肾上腺轴功能的影响
Thorax. 1993 Mar;48(3):233-8. doi: 10.1136/thx.48.3.233.
4
Clinical pharmacology of corticosteroids in bronchial asthma.支气管哮喘中皮质类固醇的临床药理学
Pharmacol Ther. 1993;58(2):173-209. doi: 10.1016/0163-7258(93)90049-j.
5
A sensitive radioimmunoassay, incorporating solid-phase extraction, for fluticasone 17-propionate in plasma.一种结合固相萃取的血浆中氟替卡松17-丙酸酯灵敏放射免疫测定法。
J Pharm Biomed Anal. 1993 Jul;11(7):557-61. doi: 10.1016/0731-7085(93)80005-l.
6
7
Lung deposition patterns of directly labelled salbutamol in normal subjects and in patients with reversible airflow obstruction.正常受试者和可逆性气流受限患者中直接标记沙丁胺醇的肺部沉积模式。
Thorax. 1993 May;48(5):506-11. doi: 10.1136/thx.48.5.506.
8
Systemic effects of high dose inhaled steroids: comparison of beclomethasone dipropionate and budesonide in healthy subjects.高剂量吸入性类固醇的全身效应：健康受试者中丙酸倍氯米松与布地奈德的比较。
Thorax. 1993 Oct;48(10):967-73. doi: 10.1136/thx.48.10.967.
9
Systemic effects of inhaled corticosteroids.吸入性糖皮质激素的全身效应。
Thorax. 1993 Oct;48(10):955-6. doi: 10.1136/thx.48.10.955.
10
Comparison of fluticasone propionate with beclomethasone dipropionate in moderate to severe asthma treated for one year. International Study Group.丙酸氟替卡松与二丙酸倍氯米松治疗中重度哮喘一年的比较。国际研究小组。
Thorax. 1993 Aug;48(8):817-23. doi: 10.1136/thx.48.8.817.
Zotero 插件